Achaogen Inc. (NASDAQ:AKAO) COO Blake Wise sold 3,632 shares of the business’s stock in a transaction that occurred on Tuesday, September 27th. The stock was sold at an average price of $4.30, for a total value of $15,617.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Achaogen Inc. (NASDAQ:AKAO) opened at 4.79 on Monday. The company’s 50-day moving average price is $4.13 and its 200 day moving average price is $3.68. The stock’s market cap is $127.79 million. Achaogen Inc. has a 12-month low of $2.59 and a 12-month high of $6.50.
Achaogen (NASDAQ:AKAO) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.20. The company had revenue of $9.14 million for the quarter, compared to analyst estimates of $5.58 million. Achaogen had a negative return on equity of 118.45% and a negative net margin of 209.23%. The firm’s revenue was down 24.1% on a year-over-year basis. During the same period last year, the business earned ($0.05) earnings per share. On average, equities analysts predict that Achaogen Inc. will post ($2.71) earnings per share for the current year.
Several analysts have recently issued reports on AKAO shares. Zacks Investment Research cut Achaogen from a “buy” rating to a “hold” rating in a report on Thursday, August 11th. SunTrust Banks Inc. reaffirmed a “buy” rating and set a $10.00 price objective on shares of Achaogen in a report on Monday, September 26th. Wedbush reaffirmed an “outperform” rating and set a $10.00 price objective on shares of Achaogen in a report on Tuesday, September 27th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Achaogen in a report on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $8.17.
Hedge funds have recently bought and sold shares of the company. ICONIQ Capital LLC raised its stake in Achaogen by 100.3% in the second quarter. ICONIQ Capital LLC now owns 28,629 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 14,333 shares during the period. A.R.T. Advisors LLC bought a new stake in Achaogen during the second quarter valued at approximately $142,000. Eagle Global Advisors LLC raised its stake in Achaogen by 55.4% in the second quarter. Eagle Global Advisors LLC now owns 38,749 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 13,812 shares during the period. Renaissance Technologies LLC raised its stake in Achaogen by 174.0% in the first quarter. Renaissance Technologies LLC now owns 64,400 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 40,900 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its stake in Achaogen by 13.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 85,472 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 10,330 shares during the period. 56.84% of the stock is currently owned by hedge funds and other institutional investors.
Achaogen Company Profile
Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.